Final rule 2026-07860
Medical Devices; Immunology and Microbiology Devices; Classification of the Alzheimer's Disease Pathology Assessment Test
The Food and Drug Administration (FDA, the Agency, or we) is classifying the Alzheimer's disease pathology assessment test into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the Alzheimer's disease pathology assessment test. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
Source-supplied record
Document details
- Document number
- 2026-07860
- Published
- Apr 22, 2026
- Effective
- Apr 22, 2026
- Comments close
- Not supplied
- Federal Register citation
- 91 FR 21379
Docket identifiers
- Docket No. FDA-2026-N-3930
CFR references
- Title 21, part 866